Payment overview · 2025
General Payments
$1,855.68
92 reported records · 18 companies
Healthcare provider profile · identity verified
Timothy Maynard
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · CEREDO, WV · NPI 1942618657
Verified facts
What the public records show
CMS Open Payments records show Timothy Maynard received $1,855.68 in general payments during 2025 across 92 reported records.
AstraZeneca Pharmaceuticals LP accounted for 28.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Nurtec Odt, Ozempic, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Invega Sustenna by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Xarelto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $531.19 | 28.6% | 13 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $304.86 | 16.4% | 20 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $257.00 | 13.8% | 17 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $144.14 | 7.8% | 14 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $99.00 | 5.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $91.10 | 4.9% | 5 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $69.72 | 3.8% | 4 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $69.51 | 3.8% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $68.60 | 3.7% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $58.00 | 3.1% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $33.80 | 1.8% | 2 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $24.30 | 1.3% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $22.00 | 1.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.14 | 1.0% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $17.35 | 0.9% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $16.48 | 0.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.00 | 0.9% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $14.49 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,756.68 | 91 |
| Education | $99.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $483.23 | 10 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $316.23 | 19 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $211.90 | 14 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $206.04 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $158.08 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $144.14 | 14 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $122.75 | 12 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $99.00 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $91.10 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $87.16 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $72.02 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $58.00 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $54.73 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $33.80 | 2 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $24.30 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $22.00 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $22.00 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.14 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $17.35 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $16.48 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $14.99 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $14.49 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $9.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 69 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 47 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
69 | 21 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
47 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
86 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 448 | 106 |
| Alprazolam | Alprazolam | 327 | 44 |
| Gabapentin | Gabapentin | 326 | 59 |
| Lisinopril | Lisinopril | 291 | 72 |
| Levothyroxine Sodium | Levothyroxine Sodium | 246 | 61 |
| Amlodipine Besylate | Amlodipine Besylate | 242 | 54 |
| Omeprazole | Omeprazole | 239 | 63 |
| Trazodone Hcl | Trazodone Hcl | 238 | 50 |
| Clonazepam | Clonazepam | 200 | 28 |
| Atorvastatin Calcium | Atorvastatin Calcium | 195 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 192 | 42 |
| Sertraline Hcl | Sertraline Hcl | 166 | 31 |
| Ezetimibe | Ezetimibe | 158 | 50 |
| Potassium Chloride | Potassium Chloride | 158 | 47 |
| Risperidone | Risperidone | 151 | 23 |
| Lorazepam | Lorazepam | 148 | 30 |
| Furosemide | Furosemide | 139 | 37 |
| Metformin Hcl | Metformin Hcl | 137 | 23 |
| Mirtazapine | Mirtazapine | 131 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 130 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 130 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 122 | 45 |
| Buspirone Hcl | Buspirone Hcl | 122 | 32 |
| Divalproex Sodium | Divalproex Sodium | 122 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 119 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 116 | 28 |
| Benztropine Mesylate | Benztropine Mesylate | 108 | 14 |
| Losartan Potassium | Losartan Potassium | 108 | 29 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 108 | 34 |
| Vascepa | Icosapent Ethyl | 104 | 28 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 102 | 15 |
| Diazepam | Diazepam | 101 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 98 | 27 |
| Lamotrigine | Lamotrigine | 98 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 97 | 20 |
| Famotidine | Famotidine | 96 | 30 |
| Aripiprazole | Aripiprazole | 87 | 22 |
| Eliquis | Apixaban | 86 | 23 |
| Olanzapine | Olanzapine | 82 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 80 | 25 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 76 | 28 |
| Haloperidol | Haloperidol | 74 | suppressed |
| Ibuprofen | Ibuprofen | 72 | 19 |
| Farxiga | Dapagliflozin Propanediol | 69 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 64 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 64 | 13 |
| Metformin Hcl Er | Metformin Hcl | 63 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 59 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 59 | 13 |
| Bupropion Xl | Bupropion Hcl | 58 | 18 |
| Mounjaro | Tirzepatide | 56 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 54 | 16 |
| Baclofen | Baclofen | 50 | 11 |
| Carvedilol | Carvedilol | 50 | 15 |
| Montelukast Sodium | Montelukast Sodium | 50 | 18 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 49 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 49 | 18 |
| Ozempic | Semaglutide | 47 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 47 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 46 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 45 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 45 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 17 |
| Sucralfate | Sucralfate | 42 | suppressed |
| Temazepam | Temazepam | 41 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | 14 |
| Donepezil Hcl | Donepezil Hcl | 40 | 15 |
| Topiramate | Topiramate | 40 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 12 |
| Pregabalin | Pregabalin | 38 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 37 | suppressed |
| Meloxicam | Meloxicam | 37 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 37 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | 16 |
| Levetiracetam | Levetiracetam | 35 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Simvastatin | Simvastatin | 32 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Allopurinol | Allopurinol | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Jardiance | Empagliflozin | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 27 | 12 |
| Atenolol | Atenolol | 27 | suppressed |
| Prednisone | Prednisone | 27 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 19 |
| Finasteride | Finasteride | 26 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 21 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 24 | suppressed |
| Glimepiride | Glimepiride | 24 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 23 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 23 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Azithromycin | Azithromycin | 17 | 12 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 17 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 17 | suppressed |
| Lacosamide | Lacosamide | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Vraylar | Cariprazine Hcl | 17 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 17 | suppressed |
| Cimetidine | Cimetidine | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Cefaclor | Cefaclor | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 12 |
| Fluconazole | Fluconazole | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Buprenorphine | Buprenorphine | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Klayesta | Nystatin | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,855.68 · 92 records | AstraZeneca Pharmaceuticals LP | ABILIFY ASIMTUFII, AIRSUPRA, ARISTADA, AUSTEDO XR, Auvelity, BREZTRI, CAPLYTA, Dyanavel XR, FARXIGA, LYBALVI, NURTEC ODT, Ohtuvayre, Ozempic, QULIPTA, REXULTI, SPRAVATO, Sunosi, TRELEGY ELLIPTA, TRINTELLIX, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, XYWAV, ZAVZPRET | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error